

Table 1. Participant characteristics at baseline

	Asthma	COPD	Controls
Patient (n)	23	16	12
Mean age (years) *	67.3 ± 7.99	74.8 ± 8.01	72.3 ± 7.78
Male/Female**	10/13	16/0	8/4
Duration (years)	10.4 ± 9.20	7.27 ± 6.13	
Smoking**	11	16	8
Severity			
Step/Gold I	3	1	
Step/Gold II	4	1	
Step/Gold III	10	11	
Step/Gold IV	6	3	
FeNO (ppb)	47.9 ± 53.8	N/A	N/A
Brinkman Index*	491.8 ± 269.3	1122.7 ± 591.0	535.3 ± 511.6
Serum IgE (IU/mL)	389.5 ± 723.4	126.3 ± 103.6	N/A
Blood eosinophils (%)	6.47 ± 7.00	2.68 ± 1.64	2.43 ± 1.88
Pulmonary function			
%FVC*	98.7 ± 14.1	87.1 ± 17.9	91.1 ± 18.0
%FEV ₁ **	88.2 ± 21.4	64.9 ± 20.9	99.6 ± 10.4
FEV _{1%} **	66.5 ± 13.5	51.5 ± 12.0	73.9 ± 14.4
%V ₅₀ **	41.4 ± 24.0	19.2 ± 14.9	60.5 ± 46.8
%V ₂₅	28.3 ± 16.7	21.6 ± 13.5	53.6 ± 59.9

Mean ± standard deviation (SD); * $P < .05$; ** $P < .01$ between asthma and COPD.

%FVC, forced vital capacity (% of predicted); %FEV₁, forced expiratory volume in 1 s (% of predicted); FEV_{1%}, forced expiratory volume in 1 s % means FEV/FVC X 100%; %V₅₀, maximum expiratory flow at 50% of the forced vital capacity (% of predicted); %V₂₅, maximum expiratory flow at 25% of the forced vital capacity (% of predicted).